Ethylene glycol residue testing in active pharmaceutical ingredients (APIs) is a critical quality control requirement governed by international standards such as ICH Q3C, USP General Chapter <467>, and Ph. Eur. 2.4.24. As a Class 2 residual solvent with documented nephrotoxicity, ethylene glycol must be accurately quantified at ppm levels to ensure patient safety and regulatory compliance. This article provides a comprehensive technical overview of the sample types, testing items, analytical methods, and practical applications involved in ethylene glycol residue determination for pharmaceutical raw materials.
Technical Overview
Ethylene glycol (EG, CAS 107-21-1) is a common process solvent used in the synthesis, crystallization, and purification of active pharmaceutical ingredients. Under the ICH Q3C guideline on residual solvents, ethylene glycol is classified as a Class 2 solvent, meaning it should be limited in pharmaceutical products to protect patient health. The permitted daily exposure (PDE) is 6.2 mg/day, corresponding to a concentration limit of 620 ppm in the drug product, assuming a maximum daily dose of 10 g of the product.
The toxicological concern is significant: ethylene glycol is metabolized to glycolaldehyde, glycolic acid, and oxalic acid, leading to central nervous system depression, metabolic acidosis, and acute kidney injury caused by calcium oxalate crystal deposition. Historical poisoning incidents involving diethylene glycol (DEG) and ethylene glycol contamination of glycerin-based preparations have made glycol residue control a high-priority issue for regulators worldwide, including investigations described in FDA guidance for pharmaceutical manufacturers.
Because ethylene glycol has a high boiling point (197.3 °C) and limited volatility, its determination is technically more demanding than that of typical Class 3 solvents. Accurate testing requires carefully optimized chromatographic conditions and rigorous method validation in accordance with ICH Q2, typically performed in accredited third-party laboratories or in-house GMP quality control facilities.
Testing Samples
Active Pharmaceutical Ingredients
APIs in which ethylene glycol is used as a reaction medium, recrystallization solvent, or processing aid are the primary sample type. Testing verifies that residual EG in the final isolated material is below the calculated acceptable limit before batch release.
Glycerin and Polyol-Based Raw Materials
Glycerin, propylene glycol, sorbitol solutions, and polyethylene glycols may be contaminated with ethylene glycol or diethylene glycol from the manufacturing supply chain. Pharmacopoeial monographs for glycerin restrict combined DEG and EG content, and these raw materials are routinely screened prior to use in drug product manufacturing.
Pharmaceutical Intermediates and Process Streams
Intermediates, mother liquors, and in-process controls are analyzed during process development and validation to demonstrate effective solvent removal in downstream steps such as washing, drying, and crystallization.
Oral Liquid and Semi-Solid Preparations
Syrups, elixirs, oral solutions, and topical formulations containing humectants or co-solvents are tested to confirm compliance of the finished dosage form with the ICH Q3C concentration limit.
Testing Items
Depending on the regulatory context and the synthesis route of the material, the following testing items are typically included in an ethylene glycol residue control strategy:
- Identification and quantitative determination of ethylene glycol residue
- Co-determination of diethylene glycol (DEG), a frequent co-contaminant
- Screening of other Class 1, Class 2, and Class 3 residual solvents per ICH Q3C
- Total glycol content in polyol-based excipients and raw materials
- Related substances and degradation products, where applicable
- Water content by Karl Fischer titration, which supports method development for hygroscopic matrices
Acceptance criteria are derived either from the default ICH Q3C concentration limit of 620 ppm or from an Option 2 calculation based on the actual maximum daily dose of the product.
Testing Methods
Headspace Gas Chromatography with Flame Ionization Detection (HS-GC-FID)
Static headspace GC-FID is the pharmacopoeial reference approach described in USP General Chapter <467> and Ph. Eur. 2.4.24 for residual solvents. For ethylene glycol, elevated headspace oven temperatures (typically 100–140 °C) and longer equilibration times are required to achieve adequate partitioning of this low-volatility analyte into the vapor phase. Polar capillary columns such as polyethylene glycol (WAX-type) or cyanopropylphenyl phases provide suitable retention and separation from DEG and matrix components.
Direct-Injection GC-FID
Direct liquid injection, with the sample dissolved in water, dimethylformamide, or dimethyl sulfoxide, often delivers better sensitivity and precision for high-boiling glycols than headspace sampling. An internal standard such as 1,3-propanediol or 1,4-butanediol is commonly used to correct for injection variability. Split injection with a programmed oven temperature ramp to 220–240 °C ensures complete elution and prevents carryover.
GC-MS Confirmation
Gas chromatography coupled with mass spectrometric detection in selected-ion monitoring mode is employed for identity confirmation, matrix interference assessment, and trace-level quantification. Mass spectral matching combined with retention time agreement provides the specificity required for regulatory submissions and out-of-specification investigations.
Alternative and Complementary Techniques
- HPLC with refractive index detection for direct quantification in non-volatile matrices
- Derivatization approaches (for example, esterification or silylation) that improve volatility and detector response
- Ion chromatography following oxidative sample preparation for total glycol determination
Method Validation
Methods are validated per ICH Q2 covering specificity, linearity across the analytical range, accuracy by recovery studies, intra-day and inter-day precision, limit of detection and limit of quantification (typically ≤ 50 ppm), solution stability, and robustness. System suitability criteria, including resolution between EG and DEG peaks, are established before routine use.
Applications
Ethylene glycol residue testing supports multiple quality and compliance functions throughout the pharmaceutical product lifecycle:
- GMP batch release testing of APIs where EG is used in the synthesis route
- Regulatory submissions, including Drug Master Files (DMF), ASMFs, NDAs, and ANDAs
- Supplier qualification and incoming material control for glycerin and polyol excipients
- Process validation and solvent-removal capability studies for drying and purification steps
- Long-term and accelerated stability programs to monitor residual solvent behavior
- Out-of-specification and contamination investigations, including supply chain integrity assessments
- Import and export compliance testing against GB, USP, Ph. Eur., and JP pharmacopoeial requirements
Pharmaceutical manufacturers, contract development and manufacturing organizations, and accredited third-party laboratories rely on these determinations to demonstrate that residual glycol levels remain within safe exposure limits across all batches.
FAQ
What is the regulatory limit for ethylene glycol residue?
Under ICH Q3C, ethylene glycol is a Class 2 solvent with a PDE of 6.2 mg/day and a default concentration limit of 620 ppm in the drug product. For products administered at higher daily doses, a lower limit must be calculated using the Option 2 approach.
Why is ethylene glycol more difficult to test than most residual solvents?
Its high boiling point of 197.3 °C and low vapor pressure reduce headspace sensitivity, so laboratories must use elevated equilibration temperatures, direct injection, or derivatization to achieve the required detection limits.
Should diethylene glycol be tested together with ethylene glycol?
Yes. DEG frequently co-occurs with EG, particularly in glycerin and polyol supply chains, and both share similar toxicity concerns. Combined testing using a validated GC method is standard practice.
How should samples be prepared for analysis?
Samples are typically dissolved in water or a high-boiling organic solvent compatible with the chromatographic system. Homogeneous solutions, controlled extraction conditions, and verified solution stability are essential for reproducible results.
How often should ethylene glycol residue testing be performed?
For APIs where EG is a process solvent, testing is performed on every commercial batch as part of release specifications. Periodic verification is also recommended when suppliers, synthesis routes, or purification conditions change.